Suzhou Novoprotein Scientific Co., Ltd. Class A

As of June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A carries a market capitalization of 2.52B, placing it among publicly traded companies globally. Its enterprise value stands at 1.73B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Suzhou Novoprotein Scientific Co., Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A has 69.92M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 16.59, and the price-to-book ratio stands at 1.26.

These figures are as of June 30, 2026. The EV/Sales ratio of 11.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.73B versus a market cap of 2.52B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A maintains a current ratio of 18.76, meaning it holds 18.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.52, indicating elevated leverage, while an interest coverage ratio of -31.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A posted a negative return on equity (ROE) of -4.43, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -4.16, reflecting losses generated across the asset base. The company generates approximately 245,320.36 in revenue per employee across its workforce of 618.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.63 indicates how many times Suzhou Novoprotein Scientific Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A recorded 16.82M in income tax expense. The company reported a pretax loss of -73.73M and -90.54M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A's stock has gained approximately 157.60% over the past 52 weeks. The 50-day moving average sits at 93.68, while the 200-day moving average is 55.16.

Over the twelve months ended June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A generated 151.73M in revenue and converted that into -90.54M in net income, yielding earnings per share of -1.29. EBITDA reached -73.45M, while operating income came in at -65.89M.

As of June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A holds 834.77M in cash and equivalents against 50.37M in total debt, resulting in a net debt position of -734.35M. Total book value stands at 2.00B, with working capital of 1.72B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A posted a gross margin of 69.46, reflecting its pricing power and cost economics. The operating margin of -43.43 and net profit margin of -59.67 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Total shareholder yield reaches 1.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Suzhou Novoprotein Scientific Co., Ltd. Class A shareholders.

As of June 30, 2026, Suzhou Novoprotein Scientific Co., Ltd. Class A has an Altman Z-Score of 11.67, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.